MUNI MED

Drug delivery approaches

Ondřej Zendulka

1 Department of Pharmacology

Structure of the lecture

- **1**. Classification of administration routes
- 2. Factors related to administration route selection
- 3. Characteristic of administration routes
- 4. Innovative administration routes

Classification of administration routes

Pharmacological differences

pharmacodynamic

- difference in the charatcer of the effect of drug

- ethanol, iodine (topically/systemic)

pharmacological

- difference in the site of action (local vs. systemic)

- H₁ antihistamines in nasal drops and tablets

- differences in onset/duration of effect, toxicity

- fentanyl i.v. vs transdermal, vancomycin per os vs. i.v.

Administration/effect of drug

Local

- drug absorption is limited
- effect aimed on target
- tissue/organ
- low risk of AE
- effect depends upon final concentration


Systemic

• drug is absorbed to systemic

circulation

- possible influence on whole body
- higher risk of AE
- effect depends on dose,
 - bioavailability and DDF

Classification of administration rotes



peroral, rectal, gastric

epicutaneous, vaginal, intraocular, intraarticular, intrathecal...

transdermal, transnasal, i.v., i.m., s.c., i.a., inhalations, i.o....

peroral, rectal, gastric

Classification of administration routes

• with regard to the disruption of natural protective barriers

Non-invasive

- vaginal, (intrauterine?)
- sublingval
- epicutaneous
- oral
- intranasal
- inhalational
- rectal

...

Invasive

- intravenous
- intraartrerial
- intraoseal
- intramuscular
- subcutaneous
- intradermal
- implants

. . .

Classification of administration routes

• with respect to administration schedule

Intermitent use

- repeated use
- plasma level fluctuation
- all administration routes
- local and systemic use

Continuous use

constant speed of drug

administration = constant plasma level of drug

- intravenous
- intramuscular
- subcatous/implants
- intravaginal/intrauterine
- intrathecal
- transdermal

Physical-chemical properties of drug

- lipophilicity/hydrophilicity, solubility
- chemical structure/size of molecule
- pH/pKa
- availability of pharmaceutical form

Therapeutic indication + severity of disease

• the same drug administered differentialy with respect to

diagnosis

- local administration prefered
- acute situations fast onset of effect required

Benefit:risk ratio

the more severe, the "more risky" administration

Comorbidities

- can block distinct administration routes
- can influence drugs efficacy

Comedication

risk of drug-drug interactions

Administration routes - local effect

• intraurethral, intravesical, intracavernal

• dental, gingival

endotracheopulmonal

Administration routes - local effect

intraaural

• intraamniotic

• intracoronar, intraarterial

MUNI MED

Ocular/conjunctival administration

- usually eye drops and ointments
- local effect
- risk of systemic AE
- specific quality requirements sterility

Intraocular administration

intravitreal implants and injections in macular

Intrathecal/intracerebral/intracerebroventricular administration

- to the subarachnoideal space
 - /brain/ brain ventricles

Intraarticular administration

- analgesics/antiphlogistics
- hyaluronic acid
- for local effect

Administration routes for local and systemic effect

- vaginal, intrauterinne
- dermal/transdermal
- intranasal/transnasal
- inhalational
- rectal
- oral/transbucal, sublingual
- peroral

Vaginal, endocervical, intrauterinal

- 1. local effect
- minimum of AE
- specific adjuvants \downarrow pH
- antibiotics, antimycotics, antiparasitics
- 2. systemic effect
- vaginal rings intrauterine devices
- controlled drug release
- contraceptives

Epicutaneous/transdermal administration

Local effect

- ointments, creams,
 - solutions, patches
- minimal AE
- dermatology

Systemic effect

- transdermal administration
- mainly patches
- continuous release
- local+systemic AE
- high compliance
- easy discontinuation

Intranasal/transnasal administration

- drops, sprays, ointments
- local effect antiseptics, ATB
- - antihistamines, decongestants
- - antiphlogistics
- systemic effect analgesics, antivirotics
 - hormones (ADH, gonadotropin, insulin)

Inhalation

- gases, aerosols
- systemic effect general anesthetics
- local effect antiasthmatics
- fast onset of effect
- minimal presystemic elimination
- administration from spray cans or other instruments (turbohaler, dischaler, nebuliser)

Rectal administration

- suppositories, capsules, tablets, foams, tampones
- alternative for peroral administration in case of nausea/vomitting or unconciousness
- variable drug absorption

Oral/sublingual/buccal administration


- fast onset of systemic effect
- oinly for small and lipiphilic molecules
- sprays, tablets, dispergable films
- analgesics fentanyl, buprenorfin
- hypnotics zolpidem

28

- vasodilators nitroglycerine
- antiemetics ondansetrone
- homeopatics, alergens, cannabis....

Peroral administration

- 1. for local effect
- minimal AE
- risk of interaction with coadministered drugs
- antacids, laxatives, antibiotics
- 2. for systemic effect
- drug absorbed from different parts of GIT
 can be influenced by DDF
- "slow" effect onset
- the effect depends on patients "compliance"



Administration routes for mainly systemic effect

- intravenous/intraosseous
- intramuscular
- subcutaneous injections and implants

Injections

intravenous, (intraarterial)

- injection/infusion
- 100% bioavailability, "immediate" effect
- true solutions + emulsions

intramuscular

- max. volume 5 ml
- to *m. glu. maximus*
- absorption: solution> emulsion> suspension

subcutaneous

- to 2 ml
- variable absorption with regard to adipose tissue

Injections

intradermal

- minimal volume
- diagnostic purposes

intraosseal

32

- alternative to i.v.
- injection/infusion
- Eg. Atropine onset of the effect
- i.v. 30-90 s; s.c. 15-30 min; i.m. 30-45 min

Implants

33

- degradable/nondegradable
- usually s.c. or intraocular
- systemic/local effect
- continuous/pulsatile release = continuous/repeated drug administration
- increased patient's compliance
- complicated discontinuation

Innovations in drug administration

- new posssibilities of administration routes are probably depleted => modification of DDF
- the goals are:
 - 1. increase of drug safety/decrease of drug toxicity
 - 2. increase the efficacy of administered dose
 - 3. increase the patient's compliance

More about innovations in drug administrations:

• Current Opinion in Pharmacology, Vol. 36, 2017